GLP-1–Based Pharmacotherapy, Oral Versus Injectable Treatment, and Medical Nutrition Therapy in Obesity Management: A Narrative Review by Ori Scott M.Sc. RD

Abstract

Obesity is a chronic, complex, and relapsing disease influenced by biological, genetic, metabolic, environmental, behavioral, socioeconomic, and pharmacological factors. The development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists has substantially changed the pharmacological management of obesity. Semaglutide and tirzepatide can produce clinically meaningful reductions in body weight, while newer oral therapies have expanded treatment options for individuals who prefer not to use injectable medications. However, pharmacotherapy should not be considered a replacement for nutrition therapy, physical activity, behavioral treatment, or longitudinal medical care.

This narrative review examines the mechanisms, efficacy, safety, route-of-administration considerations, body-composition effects, and weight recurrence associated with GLP-1–based obesity pharmacotherapy. It also evaluates evidence supporting registered dietitian–delivered medical nutrition therapy (MNT) and discusses the importance of integrating nutrition care with pharmacotherapy. Current evidence indicates that GLP-1–based therapies are among the most effective nonsurgical treatments for obesity, although gastrointestinal adverse effects are common and loss of lean tissue can accompany substantial weight reduction. Dietitian-led interventions independently improve body weight, waist circumference, blood pressure, and quality of life. Rather than viewing medication and nutrition therapy as competing approaches, contemporary obesity management should integrate pharmacological, nutritional, physical activity, and behavioral interventions according to individual clinical needs, preferences, risks, and treatment goals.

Keywords: obesity; GLP-1 receptor agonist; semaglutide; tirzepatide; orforglipron; medical nutrition therapy; dietitian; weight management; lean mass; obesity pharmacotherapy

1. Introduction

Obesity is increasingly recognized as a chronic disease rather than simply the consequence of individual behavioral choices. Body-weight regulation reflects complex interactions among the central nervous system, gastrointestinal hormones, adipose tissue, genetics, metabolism, medications, sleep, stress, food availability, socioeconomic conditions, and physical activity. Consequently, effective obesity treatment frequently requires long-term and multidisciplinary management.

The emergence of incretin-based pharmacotherapy has substantially expanded the treatment options available to people with obesity. GLP-1 receptor agonists were initially developed primarily for glycemic management in type 2 diabetes but subsequently demonstrated clinically important effects on appetite, energy intake, and body weight. Semaglutide has become an established obesity pharmacotherapy, while tirzepatide acts through both GIP and GLP-1 receptors and can produce even greater average reductions in body weight in clinical trials.

The therapeutic landscape is also changing with the development and approval of oral treatments. The availability of oral semaglutide for chronic weight management and the introduction of the nonpeptide oral GLP-1 receptor agonist orforglipron demonstrate that incretin-based obesity pharmacotherapy is no longer synonymous with injectable treatment.

Despite the effectiveness of these medications, obesity management should not be reduced to a comparison between medication and lifestyle intervention. Nutrition therapy, physical activity, behavioral interventions, pharmacotherapy, and metabolic/bariatric surgery address different components of a heterogeneous chronic disease. Registered dietitian nutritionists therefore retain an important role during pharmacological treatment, particularly when appetite suppression substantially changes food intake.

This review summarizes current evidence concerning GLP-1–based obesity pharmacotherapy and evaluates how pharmacological treatment can be integrated with dietitian-delivered MNT.

2. Physiological Basis and Mechanisms of GLP-1–Based Therapy

GLP-1 is an endogenous incretin hormone released primarily from intestinal L cells following nutrient ingestion. It contributes to glucose regulation by stimulating glucose-dependent insulin secretion and suppressing glucagon secretion when appropriate. GLP-1 signaling also affects gastric emptying and neural pathways involved in appetite regulation.

GLP-1 receptor agonists reproduce several physiological effects of endogenous GLP-1 but have pharmacokinetic properties that permit clinically useful exposure. Their weight-reducing effects are not appropriately described as simply “burning fat.” Instead, an important mechanism involves modification of biological signals controlling hunger, satiation, satiety, and energy intake.

Patients receiving effective GLP-1–based pharmacotherapy may experience earlier satiation during meals, prolonged fullness, decreased hunger between meals, and reductions in persistent food-related thoughts or cravings. These effects can substantially decrease spontaneous energy intake.

Tirzepatide differs pharmacologically from selective GLP-1 receptor agonists because it activates both GIP and GLP-1 receptors. The combined signaling appears to produce substantial metabolic and weight effects, although the complete physiological mechanisms responsible for its efficacy remain an area of active investigation.

3. Effectiveness of GLP-1–Based Pharmacotherapy

Evidence from randomized clinical trials, systematic reviews, meta-analyses, and umbrella reviews consistently demonstrates clinically important weight reduction with GLP-1–based therapies.

The STEP 1 randomized trial established the efficacy of once-weekly subcutaneous semaglutide 2.4 mg in adults with overweight or obesity without diabetes. Subsequent systematic reviews have reinforced these findings. A 2024 meta-analysis of randomized trials reported an approximately 11.5 percentage-point greater reduction in body weight with once-weekly semaglutide than with placebo. Another systematic review reported a mean relative weight reduction approximately 11.8 percentage points greater than control.

Tirzepatide has demonstrated still greater average reductions in several trials. In SURMOUNT-1, 2,539 adults with obesity or overweight and at least one weight-related complication, but without diabetes, received tirzepatide or placebo for 72 weeks. Mean body-weight changes were approximately −15.0%, −19.5%, and −20.9% with 5-, 10-, and 15-mg tirzepatide, respectively, compared with −3.1% with placebo.

A 2025 umbrella review incorporating 15 systematic reviews and meta-analyses concluded that GLP-1–based treatments produce substantial weight reductions in adults with overweight or obesity without diabetes. Tirzepatide and semaglutide demonstrated particularly large effects, although differences among study populations, doses, durations, and analytical approaches complicate indirect comparisons.

These values represent population averages rather than expected outcomes for every individual. Treatment responses vary considerably, and the magnitude of weight reduction should not be interpreted as a measure of motivation, adherence, or personal character.

4. Clinical Meaning of Weight Reduction

The objective of obesity treatment is not necessarily maximal weight loss. Treatment should aim to improve health, physical function, quality of life, and obesity-related complications while minimizing adverse effects and treatment burden.

Clinically meaningful improvements can occur with weight reductions considerably smaller than those achieved in the highest-response groups of pharmacotherapy trials. Outcomes that may improve include glycemic control, blood pressure, lipid parameters, mobility, obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease, cardiovascular risk, and quality of life.

In some individuals, preventing further weight gain or improving metabolic health without large changes in body weight may constitute a meaningful therapeutic outcome.

Accordingly, body weight should be considered one outcome among several rather than the exclusive measure of treatment success.

5. Oral Versus Injectable GLP-1 Therapy

5.1 Changing Treatment Options

Historically, GLP-1 obesity pharmacotherapy was associated primarily with subcutaneous injection. This distinction is increasingly outdated.

Semaglutide is now available in both injectable and oral formulations for weight management in appropriate adults in the United States. In addition, orforglipron, an orally administered nonpeptide GLP-1 receptor agonist, received U.S. approval in 2026 for long-term weight management in adults with obesity or overweight accompanied by at least one weight-related comorbid condition.

The availability of oral therapies increases the importance of individualized treatment selection rather than assuming that all effective incretin therapy requires injection.

5.2 Is Injection More Effective Than Oral Treatment?

The question cannot be answered solely on the basis of route of administration.

Earlier comparisons between oral and subcutaneous semaglutide frequently involved patients with type 2 diabetes and used different doses and formulations. These studies therefore should not automatically be extrapolated to modern obesity-dose oral formulations.

The phase 3 OASIS 1 trial demonstrated that high-dose oral semaglutide can produce substantial weight reduction in adults with overweight or obesity without type 2 diabetes. This finding demonstrates that oral administration itself does not preclude clinically significant efficacy.

Treatment decisions should therefore consider the specific drug, dose, formulation, clinical indication, contraindications, adverse-effect profile, dosing requirements, adherence feasibility, cost, availability, and patient preference rather than route alone.

5.3 Treatment Burden and Adherence

Route of administration can influence convenience differently for different individuals.

Subcutaneous semaglutide for obesity is generally administered once weekly. Oral semaglutide is taken daily and requires specific administration conditions, including administration on an empty stomach with a limited amount of water and a waiting period before food, beverages, or other oral medications.

In contrast, orforglipron is a once-daily oral small-molecule GLP-1 receptor agonist that can be administered without the same fasting and water restrictions.

Thus, a daily tablet is not inherently more convenient than a weekly injection. Patient preference and the ability to consistently follow administration instructions should be incorporated into shared decision-making.

6. Safety and Adverse Effects

6.1 Gastrointestinal Effects

Gastrointestinal adverse effects are the most frequently reported complications of GLP-1–based pharmacotherapy. Common symptoms include:

• nausea;

• vomiting;

• diarrhea;

• constipation;

• abdominal discomfort or pain;

• dyspepsia;

• gastroesophageal reflux symptoms; and

• early or prolonged fullness.

These effects occur particularly during treatment initiation and dose escalation and are frequently mild to moderate. Gradual dose escalation is used in part to improve gastrointestinal tolerability.

Systematic reviews of semaglutide trials consistently demonstrate increased gastrointestinal adverse events compared with placebo.

6.2 Dehydration and Kidney Function

Persistent vomiting or diarrhea may result in clinically significant volume depletion. Severe dehydration can contribute to acute kidney injury, particularly in susceptible patients. Individuals experiencing persistent gastrointestinal symptoms therefore require assessment of hydration and, when clinically appropriate, renal function.

6.3 Gallbladder Disease and Pancreatitis

Gallbladder complications, including cholelithiasis and cholecystitis, have been reported during GLP-1 receptor agonist treatment. Rapid or substantial weight loss itself can also contribute to gallstone formation.

Acute pancreatitis has been observed in patients receiving GLP-1 receptor agonists and remains an important clinical warning. Severe persistent abdominal pain, particularly when accompanied by vomiting or radiation of pain to the back, warrants prompt medical evaluation.

6.4 Thyroid C-Cell Tumor Warning

Semaglutide carries a boxed warning concerning thyroid C-cell tumors based on findings in rodents. Whether the same mechanism causes medullary thyroid carcinoma in humans has not been established.

Semaglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Appropriate medical screening is therefore necessary before treatment.

6.5 Hypoglycemia

GLP-1–based obesity pharmacotherapy does not typically cause severe hypoglycemia when used alone in individuals without diabetes. However, hypoglycemia risk can increase when these medications are combined with insulin or insulin secretagogues. Medication adjustment and glucose monitoring may therefore be required in people receiving concurrent glucose-lowering therapy.

7. Body Composition and Lean Tissue During Treatment

Substantial weight reduction involves changes in both adipose and nonadipose tissues. Loss of body weight during GLP-1 therapy should therefore not be assumed to represent exclusively adipose tissue.

A 2025 systematic review and network meta-analysis of 22 randomized controlled trials involving 2,258 participants found significant reductions in total body weight, fat mass, and lean mass during GLP-1–based therapy. Lean mass accounted for approximately one quarter of total weight loss in the pooled analysis.

This finding requires careful interpretation. Lean mass measured by dual-energy X-ray absorptiometry or related methods is not synonymous with skeletal muscle. Lean tissue measurements include water and other nonadipose tissues. Consequently, the finding that approximately 25% of weight loss may be measured as lean mass does not mean that one quarter of weight reduction necessarily represents loss of functional skeletal muscle.

Nevertheless, preservation of muscle mass, strength, and physical function is clinically important, particularly in older adults, individuals with sarcopenia risk, and patients experiencing rapid or substantial weight reduction.

Nutrition care during pharmacotherapy should therefore evaluate protein adequacy and overall nutrient intake. Resistance exercise should be encouraged when medically and physically appropriate because it provides a physiological stimulus for maintenance of muscle mass and strength.

Protein recommendations must be individualized. Higher protein intake should not automatically be prescribed to individuals with conditions such as chronic kidney disease in whom protein targets may require modification.

8. Role of the Registered Dietitian and Medical Nutrition Therapy

Registered dietitians provide substantially more than generalized dietary advice. MNT involves systematic nutrition assessment, diagnosis, intervention, monitoring, and evaluation tailored to an individual's medical and nutritional needs.

During obesity treatment, dietitians can evaluate:

• total dietary intake;

• protein adequacy;

• fiber consumption;

• hydration;

• micronutrient intake;

• meal frequency and timing;

• gastrointestinal symptoms;

• food access and affordability;

• cultural and religious food preferences;

• eating behaviors;

• diabetes management;

• kidney and liver disease;

• cardiovascular risk; and

• practical barriers to food purchasing and preparation.

These functions may become especially important during GLP-1 treatment because substantial appetite suppression can make nutritional inadequacy possible even when total energy intake is reduced appropriately.

9. Evidence for Dietitian-Led Weight Management

Dietitian-delivered weight management is independently supported by randomized clinical trial evidence.

A systematic review and meta-analysis including 62 randomized controlled trials found that interventions delivered by dietitians produced greater improvements than control conditions in BMI, percentage weight loss, waist circumference, blood pressure, and several measures of quality of life.

The pooled difference in percentage weight loss was approximately −4.0 percentage points compared with control conditions. Waist circumference was reduced by approximately 3.45 cm, and clinically relevant improvements were also observed in systolic and diastolic blood pressure.

The average weight reduction associated with dietitian-led intervention is generally smaller than that observed in trials of newer obesity medications such as semaglutide or tirzepatide. However, direct numerical comparisons are problematic because medication and nutrition trials differ in populations, treatment intensity, study design, follow-up, and comparator interventions.

More importantly, pharmacotherapy and MNT perform different therapeutic functions.

10. Dietitian Care During GLP-1 Pharmacotherapy

A 2025 systematic review and meta-analysis specifically evaluated the role of registered dietitians in randomized GLP-1 obesity trials involving adults without diabetes. Thirteen studies met inclusion criteria, but clearly identifiable dietitian-related MNT procedures were reported in only six.

This finding identifies an important limitation in the existing literature. Many pharmacotherapy trials incorporate some form of lifestyle intervention but do not adequately describe who delivered nutrition treatment, the intensity of the intervention, whether formal nutrition assessment occurred, or whether individualized MNT was provided.

Consequently, existing research does not provide a strong basis for concluding that pharmacotherapy is a replacement for registered-dietitian care. Conversely, evidence supporting MNT does not establish that nutrition intervention eliminates the need for pharmacotherapy in patients for whom medication is clinically indicated.

The two treatments should therefore be considered complementary rather than mutually exclusive.

11. Nutrition Management During GLP-1 Treatment

The substantial appetite reduction experienced by some patients changes the objective of nutrition counseling.

Simply advising an individual to “eat less” may be inappropriate when medication has already markedly reduced energy intake. The clinical focus may instead need to shift toward nutritional adequacy and gastrointestinal tolerance.

Nutrition management may include:

1. ensuring adequate protein according to individual medical requirements;

2. maintaining sufficient fluid intake;

3. promoting dietary fiber while adjusting intake according to gastrointestinal tolerance;

4. including nutrient-dense fruits, vegetables, whole grains, legumes, dairy or alternatives, and appropriate protein foods;

5. using smaller meals when early satiety is prominent;

6. eating slowly and stopping when comfortably satisfied;

7. modifying high-fat or very large meals if they exacerbate nausea or reflux;

8. monitoring constipation and other gastrointestinal symptoms;

9. evaluating potential vitamin or mineral inadequacy;

10. monitoring unintended excessive dietary restriction, food aversion, weakness, or functional decline.

Nutrition treatment should also account for diabetes, chronic kidney disease, liver disease, cardiovascular disease, gastrointestinal disorders, food allergies, socioeconomic limitations, cultural eating patterns, and other factors that affect appropriate dietary recommendations.

12. Physical Activity and Preservation of Function

Physical activity should not be considered only a method for increasing energy expenditure.

Aerobic activity can improve cardiorespiratory fitness, metabolic health, mobility, and quality of life even when its independent effect on body weight is modest. Resistance training is particularly relevant during substantial weight reduction because it can support muscle strength and preservation of lean tissue.

Exercise recommendations should be individualized according to age, baseline fitness, mobility limitations, cardiovascular risk, musculoskeletal disease, disability, and patient preference.

Functional outcomes—including strength, walking ability, balance, endurance, and capacity to perform activities of daily living—may provide clinically meaningful treatment information beyond changes on the scale.

13. Behavioral Treatment

Behavioral intervention remains an important component of comprehensive obesity care even when pharmacotherapy produces substantial biological appetite suppression.

Behavioral treatment may address self-monitoring, meal planning, stimulus control, sleep, stress management, coping strategies, problem solving, physical activity routines, medication adherence, relapse prevention, and environmental barriers.

Behavioral treatment should not be framed as correcting a lack of discipline. Instead, it provides practical skills that can support long-term management of a chronic disease.

14. Weight Recurrence Following Medication Withdrawal

One of the most important findings from incretin pharmacotherapy research is that substantial weight recurrence frequently occurs after medication discontinuation.

In the STEP 1 trial extension, participants who had received semaglutide 2.4 mg lost an average of approximately 17.3% of initial body weight during treatment. One year after withdrawal of semaglutide and the structured lifestyle intervention, participants had regained approximately two thirds of their prior weight loss. Several cardiometabolic improvements also moved toward baseline.

These findings support a chronic-disease model of obesity management.

Weight recurrence after discontinuation should not be interpreted as evidence that the patient failed treatment. Pharmacotherapy modifies biological processes contributing to appetite and body-weight regulation while treatment is active. Discontinuing therapy may allow physiological mechanisms favoring weight regain to re-emerge.

The situation is conceptually similar to other chronic conditions in which disease control may diminish when effective pharmacotherapy is withdrawn.

Long-term treatment planning should therefore include discussion of maintenance therapy, potential medication discontinuation, affordability, adverse effects, patient preferences, and strategies for continued nutrition, activity, and behavioral support.

15. Outcomes Beyond Body Weight

Clinical evaluation of obesity treatment should extend beyond kilograms lost.

Relevant outcomes may include:

• waist circumference;

• blood pressure;

• fasting glucose and glycated hemoglobin;

• lipid concentrations;

• cardiovascular risk;

• sleep apnea severity;

• liver disease markers;

• mobility;

• physical strength;

• cardiorespiratory fitness;

• medication burden;

• gastrointestinal tolerance;

• nutritional adequacy;

• quality of life; and

• ability to perform daily activities.

A person-centered approach recognizes that clinically meaningful benefit may occur even when weight loss is less than the average reported in randomized trials.

16. Integrated Model of Obesity Treatment

Contemporary obesity treatment can be conceptualized through four interconnected therapeutic domains:

Nutrition Therapy

Individualized nutrition intervention should promote nutritional adequacy, cardiometabolic health, gastrointestinal tolerance, and a sustainable eating pattern. MNT delivered by a registered dietitian is particularly valuable when complex comorbidities or pharmacotherapy-induced appetite changes are present.

Physical Activity

Aerobic activity, resistance exercise, and reductions in sedentary behavior can support cardiovascular health, mobility, physical function, and muscle preservation.

Behavioral Intervention

Behavioral strategies support adherence, self-monitoring, sleep, stress management, coping skills, environmental restructuring, and long-term disease-management skills.

Medical Intervention

Medical treatment may include anti-obesity pharmacotherapy and, when clinically appropriate, metabolic or bariatric surgery. Medication selection should account for effectiveness, contraindications, comorbidities, adverse effects, treatment burden, access, cost, and patient preferences.

These components should not be placed in competition. The optimal combination varies between individuals and may change throughout the course of treatment.

17. Obesity-Specific Guidance

Obesity should be managed as a chronic, multifactorial disease requiring longitudinal rather than episodic care.

A comprehensive treatment model:

• recognizes biological, genetic, environmental, social, and behavioral determinants of body-weight regulation;

• integrates nutrition therapy, physical activity, behavioral modification, and medical interventions;

• avoids stigmatizing assumptions that body weight reflects motivation, discipline, intelligence, or moral character;

• individualizes treatment goals according to health status, comorbidities, functional outcomes, preferences, treatment response, and quality of life;

• considers anti-obesity pharmacotherapy when clinically appropriate rather than treating medication as evidence of failure of lifestyle treatment;

• incorporates registered-dietitian MNT when nutritional adequacy, comorbidities, gastrointestinal symptoms, food access, or substantial appetite suppression require specialized nutrition management;

• monitors health and functional outcomes in addition to body weight; and

• recognizes weight recurrence after treatment withdrawal as compatible with the biological chronicity of obesity rather than personal failure.

18. Limitations of the Current Evidence

Several limitations should be considered when interpreting the literature.

First, direct comparisons among semaglutide, tirzepatide, oral therapies, dietitian interventions, and other obesity treatments are limited. Network meta-analyses can facilitate indirect comparisons but cannot fully substitute for randomized head-to-head trials.

Second, clinical trials frequently differ in eligibility criteria, baseline BMI, diabetes status, duration, medication dose, behavioral intervention, dietary counseling, and analytical methods.

Third, “lifestyle intervention” is inconsistently defined across pharmacotherapy trials. The presence of dietary counseling does not necessarily indicate individualized MNT delivered by a registered dietitian.

Fourth, body-composition studies vary substantially in measurement techniques and populations. Lean mass should not be interpreted as equivalent to skeletal muscle mass or physical function.

Finally, rapid changes in available pharmacotherapies and regulatory approvals mean that systematic reviews may become outdated relatively quickly, particularly regarding oral GLP-1 treatment.

19. Future Research

Future obesity pharmacotherapy trials should more clearly document the nutritional and behavioral interventions provided alongside medication.

Research priorities include:

• randomized evaluation of structured MNT combined with GLP-1 pharmacotherapy;

• clearer reporting of registered-dietitian involvement;

• direct comparisons of modern oral and injectable formulations;

• long-term assessment of muscle mass, muscle strength, and physical function;

• identification of optimal nutrition strategies during profound appetite suppression;

• individualized protein recommendations during pharmacological weight reduction;

• strategies for preventing or managing weight recurrence following medication discontinuation;

• long-term safety and adherence studies of oral GLP-1 therapies; and

• assessment of access, affordability, health equity, and patient preferences.

20. Conclusion

GLP-1–based pharmacotherapies have transformed the medical management of obesity. Semaglutide and tirzepatide produce substantial average weight reduction, and the emergence of effective oral GLP-1 treatments provides additional therapeutic options. Gastrointestinal adverse effects remain common, and careful medical screening is required because clinically important complications and contraindications exist.

Substantial weight reduction can also involve loss of lean tissue, emphasizing the importance of adequate nutrition, appropriate protein intake, resistance exercise, and monitoring of physical function.

Registered-dietitian–delivered MNT is itself an evidence-based intervention that improves weight-related, cardiovascular, and quality-of-life outcomes. Medication and dietitian treatment therefore should not be conceptualized as competing therapies. Pharmacotherapy primarily modifies biological mechanisms influencing appetite and metabolism, whereas MNT evaluates nutritional adequacy, eating patterns, medical comorbidities, gastrointestinal tolerance, food access, and sustainable dietary behaviors.

The most appropriate clinical question is therefore not whether diet, medication, pills, or injections are universally superior. The relevant question is which combination of nutrition therapy, physical activity, behavioral intervention, and medical treatment provides the greatest health benefit with acceptable risk and treatment burden for a particular individual.

This integrated approach is consistent with the modern understanding of obesity as a chronic disease and supports treatment that prioritizes health, function, quality of life, nutritional adequacy, patient autonomy, and dignity.

Bibliography

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183.

2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038.

3. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. doi:10.1111/dom.14725.

4. Knop FK, Aroda VR, do Vale RD, et al.; OASIS 1 Investigators. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): A randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2023;402(10403):705-719. doi:10.1016/S0140-6736(23)01185-6.

5. Academy of Nutrition and Dietetics Evidence Analysis Center. Weight management interventions provided by a dietitian for adults with overweight or obesity: An Evidence Analysis Center systematic review and meta-analysis. Journal of the Academy of Nutrition and Dietetics. 2023. PMID:35788061.

6. Dorneles G, Algeri E, Lauterbach G, Pereira M, Fernandes B. Efficacy and safety of once-weekly subcutaneous semaglutide in overweight or obese adults: A systematic review with meta-analysis. 2024;132(6):316-327. doi:10.1055/a-2303-8558.

7. Kommu S, Berg RL. Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Obesity Reviews. 2024;25(9). doi:10.1111/obr.13792.

8. Moiz A, Levett JY, Filion KB, et al. Long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. American Journal of Cardiology. 2024;222:121-130. doi:10.1016/j.amjcard.2024.04.041.

9. Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism. 2025;164:156113. doi:10.1016/j.metabol.2024.156113.

10. Zamanian N, Imani H, Talebi S, Rahimlou M, Amiri Khosroshahi R, Mohammadi H. The efficacy and safety of glucagon-like peptide-1 receptor agonists in non-diabetic adults with overweight/obesity: An umbrella review of systematic reviews and meta-analyses. European Journal of Pharmacology. 2025;1003:177966. doi:10.1016/j.ejphar.2025.177966.

11. Moiz A, Filion KB, Toutounchi H, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: A systematic review of randomized controlled trials. Annals of Internal Medicine. 2025;178(2):199-217. doi:10.7326/ANNALS-24-01590.

12. Moetaz I, Abumweis S, Alqadi S, AbuGhoush M. The role of the dietitian in weight management of adults with obesity without diabetes using glucagon-like peptide-1 agonist receptors: A systematic review and meta-analysis of randomised controlled clinical trials. Clinical Obesity. 2025;15(6). doi:10.1111/cob.70030.

13. Karedath J, Nall S, Kaur M, et al. Comparative effectiveness and safety of oral versus subcutaneous semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis. Cureus. 2025;17(4). doi:10.7759/cureus.82497.

14. Lim et al. Weight loss with GLP-1 agonists in nondiabetic adults: Systematic review and network meta-analysis. Obesity. 2026. doi:10.1002/oby.70169.

15. Shirley M. Orforglipron: First approval. Drugs. 2026. doi:10.1007/s40265-026-02363-5.

16. U.S. Food and Drug Administration. Wegovy (semaglutide) injection and tablets: Prescribing Information. Revised February 2026.

17. U.S. Food and Drug Administration. Foundayo (orforglipron): Prescribing Information. 2026.

18. Shah E, AlShiab R, Abdo A, Ozbek L, Covic A, Kanbay M. Clinical management of weight regain and cardiometabolic consequences after discontinuation of GLP-1 receptor agonists. Diabetes, Obesity and Metabolism. 2026;28(6):4546-4558. doi:10.1111/dom.70713.